Comparing two beta blockers for heart health in dialysis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the cardiovascular outcomes of hemodialysis patients treated with metoprolol succinate, a dialyzable beta blocker, versus carvedilol, a non-dialyzable beta blocker. Approximately 35,000 Veterans with end-stage kidney disease will be involved, as they face high cardiovascular morbidity and mortality rates. The study will utilize a point-of-care randomized controlled trial design to assess which medication leads to better survival rates and overall heart health. Additionally, the trial will explore practices that enhance patient engagement and treatment sustainability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* On hemodialysis
* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol

Exclusion Criteria:

* Impaired decision-making capacity
* Patients not receiving carvedilol who have a history of asthma
* known hypersensitivity to any component of either drug
* Provider unwilling to sign a new medication order for a randomized patient
* No surrogate consent will be allowed

Where it's running

• VA Long Beach Healthcare System, Long Beach, CA
  Long Beach, California, United States Recruiting
• Rocky Mountain Regional VA Medical Center, Aurora, CO
  Aurora, Colorado, United States Recruiting
• North Florida/South Georgia Veterans Health System, Gainesville, FL
  Gainesville, Florida, United States Recruiting
• Jesse Brown VA Medical Center, Chicago, IL
  Chicago, Illinois, United States Recruiting
• Iowa City VA Health Care System, Iowa City, IA
  Iowa City, Iowa, United States Recruiting
• Minneapolis VA Health Care System, Minneapolis, MN
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Christopher M Donnelly
• Email: Christopher.Donnelly2@va.gov

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ribupatide PK in People with Kidney Impairment

  This study tests how a single shot of ribupatide behaves in the body for people with severe kidney problems compared to those with normal kidney function.

  Recruiting at 2 sites Phase 1 Kailera · Orlando, Florida and 1 other locations · NCT07793929

• Intradiay dialysis exercise to improve posture in adults with end-stage kidney disease

  This study tests whether a 12-week supervised exercise program done during dialysis can improve posture in adults on maintenance hemodialysis.

  Recruiting Pardis Specialized Wellness Institute · Isfahan · NCT07720401

• Pumpkin seed oil for people on hemodialysis

  This study tests whether taking pumpkin seed oil daily for 3 months helps reduce inflammation and improve-related lab markers in people with end-stage kidney disease on dialysis.

  Recruiting Al-Mustansiriyah University · Baghdad, Karkh · NCT07710183

• Porcine thymokidney transplant for end-stage renal disease

  This study tests whether a GalKO porcine thymokidney transplant can keep kidney function without dialysis in adults with end-stage kidney disease who are unlikely to get a standard donor kidney soon.

  Recruiting Phase 1 Xeno Holdings (US), LLC dba ChoironeX · New York, New York and 1 other locations · NCT07696962

• How inflammatory diseases change the way your body handles medicines.

  This study will see if inflammatory conditions like type 2 diabetes, IBD, or end-stage kidney disease change how common medicines are processed and increase the chance of side effects.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07360938

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.